The estimated Net Worth of Michael J. Detke is at least $4.27 Миллион dollars as of 10 August 2021. Michael Detke owns over 10,000 units of Cortexyme Inc stock worth over $19,500 and over the last 5 years he sold CRTX stock worth over $3,148,424. In addition, he makes $1,100,170 as Chief Medical Officer at Cortexyme Inc.
Sign up
Michael Detke CRTX stock SEC Form 4 insiders trading
Michael has made over 5 trades of the Cortexyme Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of CRTX stock worth $22,300 on 10 August 2021.
The largest trade he's ever made was selling 58,261 units of Cortexyme Inc stock on 6 July 2021 worth over $3,148,424. On average, Michael trades about 12,065 units every 69 days since 2020. As of 10 August 2021 he still owns at least 10,000 units of Cortexyme Inc stock.
You can see the complete history of Michael Detke stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Michael Detke biography
Dr. Michael Detke M.D., Ph.D. serves as Chief Medical Officer of the Company. Dr. Detke has over 25 years of research experience and extensive clinical and drug development expertise. Prior to joining Cortexyme, Dr. Detke served as the Chief Medical Officer at Embera NeuroTherapeutics, Inc. from September 2016 to December 2018, and he served as President of Detke Biopharma Consulting LLC from April 2013 to December 2018, including as Chief Medical Officer for CoMentis Pharmaceuticals. He served as Chief Medical Officer and Director of the MedAvante Research Institute of MedAvante, Inc. Dr. Detke joined MedAvante from Eli Lilly, Inc. where he served as Executive Director and head of early phase development of CNS therapeutics. At Lilly, he led clinical development of one of the industry’s deepest and strongest pipelines of CNS products. He served as Senior Medical Director responsible for Phase III development for Cymbalta and Phase IV for Prozac. Dr. Detke has served as an Adjunct volunteer Clinical Professor of Psychiatry at Indiana University School of Medicine since July 2000. Dr. Detke holds a B.A. and M.S. in Psychology from Yale University and an M.A., M.D. and Ph.D. in Psychology and Behavioral Pharmacology from the University of Pennsylvania. He also received post-doctoral training in Psychiatry from Harvard Medical School.
What is the salary of Michael Detke?
As the Chief Medical Officer of Cortexyme Inc, the total compensation of Michael Detke at Cortexyme Inc is $1,100,170. There are no executives at Cortexyme Inc getting paid more.
How old is Michael Detke?
Michael Detke is 53, he's been the Chief Medical Officer of Cortexyme Inc since 2018. There are 9 older and 8 younger executives at Cortexyme Inc. The oldest executive at Cortexyme Inc is Una Ryan, 78, who is the Lead Independent Director.
What's Michael Detke's mailing address?
Michael's mailing address filed with the SEC is C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at Cortexyme Inc
Over the last 21 years, insiders at Cortexyme Inc have traded over $59,595,534 worth of Cortexyme Inc stock and bought 19,273,711 units worth $164,053,955 . The most active insiders traders include & Johnson Johnson & Johnson..., Farmaceutici Sp A Chiesi и Ansbert Gadicke. On average, Cortexyme Inc executives and independent directors trade stock every 59 days with the average trade being worth of $475,426. The most recent stock trade was executed by Caryn Gordon Mc Dowell on 6 June 2022, trading 10,800 units of CRTX stock currently worth $30,888.
What does Cortexyme Inc do?
Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer's disease. Cortexyme is targeting a specific, infectious pathogen found in the brain and other organs and tied to degeneration and inflammation in humans and animal models.
What does Cortexyme Inc's logo look like?
Complete history of Michael Detke stock trades at Cortexyme Inc
Cortexyme Inc executives and stock owners
Cortexyme Inc executives and other stock owners filed with the SEC include:
-
Michael Detke,
Chief Medical Officer -
Margaret Mcloughlin,
Independent Director -
Casey C. Lynch,
Co-Founder, Chairman, Pres & CEO -
Christopher Senner,
Independent Director -
Dr. Michael J. Detke M.D., Ph.D.,
Chief Medical Officer -
Dr. Leslie J. Holsinger Ph.D.,
Exec. VP of R&D -
Casey Lynch,
Chairman of the Board, President, Chief Executive Officer, Co-Founder -
Christopher P. Lowe M.B.A.,
COO, CFO & Treasurer -
Caryn Gordon McDowell,
Chief Legal & Admin. Officer and Corp. Sec. -
Stephen Dominy,
Co-Founder, Chief Scientific Officer, Director -
Una Ryan,
Lead Independent Director -
Kevin Young,
Independent Director -
Christopher Lowe,
Chief Financial Officer, Treasurer -
David Lamond,
Independent Director -
Dr. Stephen S. Dominy,
Co-Founder, Chief Scientific Officer & Director -
Caryn McDowell,
Chief Legal and Administrative Officer, Corporate Secretary -
Leslie Holsinger,
Executive Vice President - Preclinical Development -
Dr. Karen L. Smith L.L.M, L.L.M., M.B.A., M.D., PH.D.,
Chief Medical Officer -
Brendan Hannah M.B.A.,
Chief Bus. Officer -
Dr. Dirk Thye M.D.,
CEO & Director -
Mary Ellen Sillivos,
VP of HR -
Stacy Roughan,
VP of Corp. Communications & IR -
Ted Monohon,
VP of Fin. & Chief Accounting Officer -
Ansbert Gadicke,
-
James B Tananbaum,
Director -
Christopher T Phd Walsh,
Director -
Richard W Dugan,
Director -
M Cory Zwerling,
Director -
Luke Evnin,
-
Michael Steinmetz,
-
Kurt Wheeler,
-
Nicholas Galakatos,
Director -
Bioventures Ii Qp Lpmpm Bio...,
-
Dana Charles Hilt,
SVP of Clinical Develop. & CMO -
Philip S Low,
Director -
Marwan Sabbagh,
Director -
Brendan Hannah,
Chief Business Officer -
Dirk Thye,
Chief Executive Officer -
Karen L. Smith,
Chief Medical Officer -
Laura Shawver,
Director -
Michael Thomas Heffernan,
Director -
Andreas Maetzel,
VP, Clinical and Regulatory -
Robert Stephan,
Director -
Alan Roberts,
VP, Scientific Affairs -
Craig A Collard,
President and CEO -
James A Harper,
Director -
Ira Duarte,
Principal Accounting Officer -
Alastair Stuart Mcewan,
Director -
Farmaceutici Sp A Chiesi,
10% owner -
Christopher George Codeanne,
Director -
Joshua B Franklin,
VP, Sales and Marketing -
Marco Vecchia,
Director -
Kenneth Mc Bean,
President -
Anton Giorgio Failla,
Director -
Michael David Enright,
Director -
Ventures, Inc.Takeda Pharma...,
-
Paul D Rubin,
President and CEO -
Inc Pfizer Ventures (Us) Ll...,
-
Pierre Lamond Christine Lamond,
-
Walter Newman,
Chief Scientific Officer/VP RD -
Howland Shaw Warren,
Director -
Frederick Finnegan,
VP of Sales and Marketing -
Robert H Zeiger,
Director -
Technology Ventures Vii Lp ...,
-
Christopher Mirabelli,
Director -
Ventures Vi Lphealthcare Pa...,
-
Jean George,
Director -
Ventures, Inc. Med Immune,
10% owner -
Bioventures Iii Qp Lpmpm Bi...,
-
Jean Advanced Technology Ve...,
-
Frank E Thomas,
CFO, VP Finance and Treasurer -
& Johnson Johnson & Johnson...,
-
Alessandro Chiesi,
Director -
Vincent T. Morgus,
EVP, Finance and CFO -
Brian Dickson,
Chief Medical Officer -
Steven Michael Lutz,
Executive Vice President -
David Price,
Chief Financial Officer -
Bio Pharma Holdings, Ltd. C...,
10% owner -
Scott B Townsend,
VP OF LEGAL AFFAIRS AND SEC. -
Jeffrey E Young,
VP FINANCE, CAO AND TREASURER -
Trevor Phillips,
COO, VP of Operations and Sec. -
George Arthur Esgro,
Vice President Sales -
Chenyqua Michele Baldwin,
Vice President Finance -
Thomas Patrick Kelly,
CFO & SVP Finance & Corp. Dev, -
Capital Group, Llc Boeding ...,
-
Kristen Gafric,
SVP, Legal & Administration -
Inc Pfizer Strategic Invest...,
-
Ted Monohon,
Chief Accounting Officer & VP -
June Bray,
Director